SEC Form 4 · accession 0001209191-16-132318

AYTU BIOPHARMA, INC · AYTU

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — VP of Commercial Operations

Period of report

Jul 7, 2016

Accepted (ET)

Jul 11, 2016 · 5:01 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001385818

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jul 7, 2016	A	140,000	$0.00	A	140,000	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option Grant^F3	$18.12	Jul 7, 2016	D	16,667	D	—	Nov 11, 2025	Common Stock	16,667	0	D
Employee Stock Option Grant^F3	$3.23	Jul 7, 2016	A	16,667	A	—	Nov 11, 2025	Common Stock	16,667	16,667	D
Employee Stock Option Grant^F5	$3.23	Jul 7, 2016	A	23,333	A	—	Jul 7, 2026	Common Stock	23,333	23,333	D
Employee Stock Option Grant^F2,F3	$18.12	holding	—	—	—	—	Nov 11, 2025	Common Stock	16,667	16,667	D

F1These are restricted shares that vest on July 7, 2026, subject to earlier vesting in certain situations.
F2The number of shares has been decreased and the exercise price has been increased to reflect the twelve-for-one stock split effected on June 30, 2016.
F333.3% vest on November 11, 2016, 33.3% vest on November 11, 2017 and 33.3% vest on November 11, 2018, subject to the Grantee's continued service as an employee on such dates.
F4These two transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option.
F533.3% vests on the one year, two year and three year anniversary of the date of grant, subject to the Grantee's continued service as an employee on such dates.